SCHEMBL906893

SCHEMBL906893

CCn1cc2cc([Sn](C)(C)C)ccc2n1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 1/20 0.34
MAT2A P31153 1/20 0.34
NOTUM Q6P988 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MLLT1 Q03111 1/20 0.31
IRAK4 Q9NWZ3 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
PIK3CD O00329 1/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31
PI4KA P42356 1/20 0.31
PIK3CG P48736 1/20 0.31
PI4KB Q9UBF8 1/20 0.31
COMT P21964 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL906596 0.77 KDM4E (0.46) NOTUMKDM4EALDH1A1
SCHEMBL24930547 0.77 CYP1A2 (0.41) SLC5A2NOTUMHTTSMN1; SMN2KDM4E
SCHEMBL21191965 0.76 NPC1 (0.40) SLC5A2MAT2ANOTUMHTTKDM4E
SCHEMBL28199810 0.76 SLC5A2 (0.35) SLC5A2MAT2ANOTUMHTTSMN1; SMN2
SCHEMBL188317 0.76 KDM4E (0.43) SLC5A2MAT2AHTTSMN1; SMN2KDM4E
SCHEMBL29141451 0.76 SLC5A2 (0.35) SLC5A2MAT2ANOTUMHTTSMN1; SMN2
SCHEMBL1637329 0.76 HDAC8 (0.39) SLC5A2MAT2ANOTUMHTTSMN1; SMN2
SCHEMBL904601 0.73 SLC5A2 (0.41) SLC5A2MAT2ANOTUMHTTSMN1; SMN2
SCHEMBL904586 0.73 SLC5A2 (0.46) SLC5A2MAT2ANOTUMHTTSMN1; SMN2
SCHEMBL22020836 0.73 NPC1 (0.38) SLC5A2MAT2ANOTUMHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182460-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION 2024-06-06 US disclosed
EP-2276759-B1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES LILLY CO ELI (US) 2011-10-19 EP disclosed
US-7932274-B2 3-indazolyl-4-pyridylisothiazoles ELI LILLY AND COMPANY (US) 2011-04-26 US disclosed
EP-2276759-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES Eli Lilly & Company (US) 2011-01-26 EP disclosed
US-20090253750-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES ELI LILLY AND COMPANY 2009-10-08 US disclosed
WO-2009123855-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES ELI LILLY AND COMPANY (US) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253750-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES CYP3A4, IPO4, JAK3 SLC5A2 180/4885MAT2A 4066/4885NOTUM 1498/4885
US-20240182460-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 SLC5A2 2949/4885MAT2A 4185/4885NOTUM 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.